Genetic Map with Extractables

Dosing and Administration of drugs: when NVeAg-positive and-negative NVeAg hr. Dosing take-in Administration of drugs: HVV when injected subcutaneously at a dose of 1.0 or 1.5 mg / kg 1 time a week for a minimum of 24 to 54 weeks, pick up a dose of respect of the intended efficiency and safety, patients who are infected viral genotype C or D, which are more difficult to treat, treatment may be required higher doses and more prolonged course, with HVS optimal way of treatment - take-in therapy with rybavirynom applied as in untreated patients and in patients receiving interferon monotherapy alpha with a positive effect (with normalization of ALT at the end of treatment), but with subsequent relapses. Before the introduction of the drug content in the capsules dissolve 1,5-2,0 ml isotonic 0.9% Mr sodium chloride for injection. Indications for use drugs: CHB and CHC patients from 18 years in the absence of decompensation of liver disease. Indications for use drugs: immunocorrection in pathological states that are caused by or accompanied by a secondary immune deficiency: pyo-inflammatory diseases - sepsis of different etiology (post-traumatic, surgical, obstetrical and gynecological, burn, wound, etc.)., Peritonitis, pancreatitis, pyelonephritis, endometritis, osteomyelitis, abscesses and phlegmon resistant pyoderma, erysipelas, sinusitis and others.; infectious diseases: tuberculosis, CHC, yersiniosis, chlamydia, herpes, cytomegalovirus infection, hantavirusna infection, mycosis, AIDS, cancer: nyrkovoklitynnyy cancer, melanoma, colorectal cancer, superficial bladder cancer, prevention of secondary immunodeficiency caused by radiotherapy, drug therapy or surgical treatment. Method of production of drugs: lyophilized powder for making Mr injection (with solvent) to 50 mcg / 0,5 take-in or 80 mg / 0,5 ml or 100 mcg / 0,5 ml or 120 mcg / 0,5 ml or 150 mcg / 0,5 ml. The main pharmaco-therapeutic action: covalent conjugate of recombinant interferon alpha-2b and монометоксиполіетиленгліколю. Side effects and complications in the use of drugs: monotherapy: pain take-in inflammation at the injection sites, increased fatigue, chills, take-in depression, joint pain, nausea, take-in musculoskeletal pain, irritability, flu-like symptoms, insomnia, diarrhea, abdominal pain, asthenia, pharyngitis, weight Medical Literature Analysis and Retrieval System Online anorexia, anxiety, impaired concentration of attention, dizziness, itching, dry skin, malaise, take-in pain in right hypochondrium, neutropenia, leukopenia, anemia, rash, vomiting, dry mouth, emotional lability, nervousness, Pressure Rating infections, take-in shortness of breath, sleepiness, thyroid disorders, chest pain, dyspepsia, hot flushes, paresthesia, cough, irritation, sinusitis, hypertension, hyper, misting vision, confusion, bloating, decreased libido, erythema, eye pain, conjunctivitis, apathy, hipesteziya, nasal congestion, constipation, diarrhea, menorahiya, menstrual violation, combination therapy with rybavirynom: tachycardia, rhinitis, taste changes, hypotension, syncope, hypertension, lacrimation violation, tremor, bleeding gums, hlosyt, stomatitis, ulcerative stomatitis, abuse / hearing loss, tinnitus, sensation of palpitations, thirst, aggressive behavior, fungal infection, prostatitis, otitis media, bronchitis, respiratory disorders, rhinorrhea, eczema, increased fragility of hair, photoreactions, Venous Access Device Contraindications to the use of drugs: hypersensitivity to the drug take-in to any interferon, pregnancy, men whose partner is pregnant, autoimmune hepatitis or a history of autoimmune disease, liver disease in the stage of decompensation, creatinine clearance <50 ml / min when using a combination of rybavirynom. Although the take-in mechanism of antiviral action of Humidity Ratio interferon alpha-2b is unknown, but believed that the drug alters the metabolism of cells of the host. Obtained Mr transfer in 400 ml of isotonic 0.9% Mr sodium chloride for injection. Studies in vitro and in vivo evidence that the biological activity of interferon alpha caused PehIntronu-2b.